User Engagement, Acceptability, and Clinical Markers in a Digital Health Program for Nonalcoholic Fatty Liver Disease: Prospective, Single-Arm Feasibility Study

被引:0
|
作者
Bjoernsdottir, Sigridur [1 ]
Ulfsdottir, Hildigunnur [2 ]
Gudmundsson, Elias Freyr [2 ]
Sveinsdottir, Kolbrun [2 ]
Isberg, Ari Pall [2 ]
Dobies, Bartosz [2 ]
Magnusdottir, Gudlaug Erla Akerlie [2 ]
Gunnarsdottir, Thrudur [2 ]
Karlsdottir, Tekla
Bjornsdottir, Gudlaug [3 ,4 ]
Sigurdsson, Sigurdur [3 ,4 ]
Oddsson, Saemundur [2 ]
Gudnason, Vilmundur [3 ,4 ]
机构
[1] Karolinska Inst, Dept Endocrinol Metab & Diabet, Solnavagen 1, S-17177 Stockholm, Sweden
[2] Sidekick Hlth, Kopavogur, Iceland
[3] Iceland Heart Assoc, Kopavogur, Iceland
[4] Univ Iceland, Fac Med, Sch Hlth Sci, Reykjavik, Iceland
关键词
digital health program; nonalcoholic fatty liver disease; NAFLD; cardiometabolic health; digital therapeutics; liver; chronic; hepatic; cardiometabolic; cardiovascular; cardiology; weight; acceptability; digital health; metabolic syndrome; diabetic; diabetes; diabetics; type; 2; BMI; lifestyle; exercise; physical activity; coaching; diet; dietary; nutrition; nutritional; patient education; coach; feasibility; fat; body composition; WEIGHT-LOSS; LIFE-STYLE; ASSOCIATION; STEATOSIS; NAFLD; RISK;
D O I
10.2196/52576
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease in the world. Common comorbidities are central obesity, type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome. Cardiovascular disease is the most common cause of death among people with NAFLD, and lifestyle changes can improve health outcomes. Objective: This study aims to explore the acceptability of a digital health program in terms of engagement, retention, and user satisfaction in addition to exploring changes in clinical outcomes, such as weight, cardiometabolic risk factors, and health-related quality of life. Methods: We conducted a prospective, open-label, single-arm, 12-week study including 38 individuals with either a BMI >30, metabolic syndrome, or type 2 diabetes mellitus and NAFLD screened by FibroScan. An NAFLD-specific digital health program focused on disease education, lowering carbohydrates in the diet, food logging, increasing activity level, reducing stress, and healthy lifestyle coaching was offered to participants. The coach provided weekly feedback on food logs and other in-app activities and opportunities for participants to ask questions. The coaching was active throughout the 12-week intervention period. The primary outcome was feasibility and acceptability of the 12-week program, assessed through patient engagement, retention, and satisfaction with the program. Secondary outcomes included changes in weight, liver fat, body composition, and other cardiometabolic clinical parameters at baseline and 12 weeks. Results: In total, 38 individuals were included in the study (median age 59.5, IQR 46.3-68.8 years; n=23, 61% female). Overall, 34 (89%) participants completed the program and 29 (76%) were active during the 12-week program period. The median satisfaction score was 6.3 (IQR 5.8-6.7) of 7. Mean weight loss was 3.5 (SD 3.7) kg (P<.001) or 3.2% (SD 3.4%), with a 2.2 (SD 2.7) kg reduction in fat mass (P<.001). Relative liver fat reduction was 19.4% (SD 23.9%). Systolic blood pressure was reduced by 6.0 (SD 13.5) mmHg (P=.009). The median reduction was 0.14 (IQR 0-0.47) mmol/L for triglyceride levels (P=.003), 3.2 (IQR 0.0-5.4) mu U/ml for serum insulin (s-insulin) levels (P=.003), and 0.5 (IQR -0.7 to 3.8) mmol/mol for hemoglobin A(1c) (HbA(1c)) levels (P=.03). Participants who were highly engaged (ie, who used the app at least 5 days per week) had greater weight loss and liver fat reduction. Conclusions: The 12-week-long digital health program was feasible for individuals with NAFLD, receiving high user engagement, retention, and satisfaction. Improved liver-specific and cardiometabolic health was observed, and more engaged participants showed greater improvements. This digital health program could provide a new tool to improve health outcomes in people with NAFLD.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Salvage surgery for patients with residual disease after concurrent chemoradiation therapy for locally advanced cervical cancer: A prospective, single-arm clinical study
    Zou, Dongling
    Li, Xiuying
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S265 - S265
  • [42] Clinical Outcome of Renal Artery Stenting for Hypertension and Chronic Kidney Disease up to 12 Months in the J-RAS Study - Prospective, Single-Arm, Multicenter Clinical Study -
    Fujihara, Masahiko
    Yokoi, Yoshiaki
    Abe, Takaaki
    Soga, Yoshimitsu
    Yamashita, Takehiro
    Miyashita, Yusuke
    Nakamura, Masato
    Yokoi, Hiroyoshi
    Ito, Sadayoshi
    CIRCULATION JOURNAL, 2015, 79 (02) : 351 - 359
  • [43] Reduced Liver Fat and Improved Cardiometabolic Health in Individuals With Non Alcoholic Fatty Liver Disease After a 12 Week Digital Intervention - A Feasibility Study
    Bjornsdottir, Sigridur
    Ulfsdottir, Hildigunnur
    Gudmundsson, Elias F.
    Sveinsdottir, Kolbrun
    Isberg, Ari P.
    Bjornsdottir, Gudlaug
    Sigurdsson, Sigurdur
    Oddsson, Saemundur
    Gudnason, Vilmundur
    CIRCULATION, 2023, 147
  • [44] Conversational Agents as Mediating Social Actors in Chronic Disease Management Involving Health Care Professionals, Patients, and Family Members: Multisite Single-Arm Feasibility Study
    Kowatsch, Tobias
    Schachner, Theresa
    Harperink, Samira
    Barata, Filipe
    Dittler, Ullrich
    Xiao, Grace
    Stanger, Catherine
    Wangenheim, Florian, V
    Fleisch, Elgar
    Oswald, Helmut
    Moeller, Alexander
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2021, 23 (02)
  • [45] Feasibility of an exercise-nutrition-psychology integrated rehabilitation model based on mobile health and virtual reality for cancer patients: a single-center, single-arm, prospective phase II study
    Qi, Yuan
    Wang, Mengjie
    Xue, Ya
    Yue, Jingyan
    Qi, Chunjian
    Shang, Weihu
    Meng, Weifen
    Zhu, Wenyu
    Pu, Xiaolin
    Li, Dongqing
    Jiang, Hua
    BMC PALLIATIVE CARE, 2024, 23 (01):
  • [46] Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Saito, Naoto
    Nakano, Yuya
    Nakano, Sachi
    Hazama, Yoichi
    Yoshida, Sachiko
    Hachisu, Yoko
    Tanaka, Yoshiki
    Kashiwabara, Kenji
    Yoshinaga, Teruo
    Tojima, Hiroki
    Naganuma, Atsushi
    Uraoka, Toshio
    INTERNAL MEDICINE, 2021, 60 (14) : 2167 - 2174
  • [47] Smartphone Application-Based Voice and Speech Training Program for Parkinson Disease: Feasibility and Satisfaction Study With a Preliminary Rater-Blinded Single-Arm Pretest and Posttest Design
    Lee, Sol-Hee
    Kim, Jiae
    Kim, Han-Joon
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2025, 27
  • [48] Feasibility and acceptability of an evidence-informed digital intervention to support self-management in people with non-alcoholic fatty liver disease: protocol for a non-randomised feasibility study (VITALISE)
    Avery, Leah
    Smith, Hollie
    McPherson, Stuart
    Hallsworth, Kate
    PILOT AND FEASIBILITY STUDIES, 2023, 9 (01)
  • [49] Feasibility and acceptability of an evidence-informed digital intervention to support self-management in people with non-alcoholic fatty liver disease: protocol for a non-randomised feasibility study (VITALISE)
    Leah Avery
    Hollie Smith
    Stuart McPherson
    Kate Hallsworth
    Pilot and Feasibility Studies, 9
  • [50] Mucosal Healing and Clinical Efficacy of Adalimumab in Small Intestinal Crohn's Disease (SIMCHA Study): Final Results From a Prospective, Open-Label, Single-Arm Study
    Wetwittayakhlang, Panu
    Verdon, Christine
    Starr, Michael
    Hahn, Gustavo Drugg
    Golovics, Petra A.
    Bessissow, Talat
    Afif, Waqqas
    Wild, Gary
    Bitton, Alain
    Lakatos, Peter L.
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2023, 34 (06): : 603 - 610